Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature
暂无分享,去创建一个
[1] Zhulan Cai,et al. The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies , 2023, Aging and disease.
[2] Marc P. Bonaca,et al. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis , 2022, European heart journal.
[3] R. Spelat,et al. Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction , 2022, Biomolecules.
[4] L. Bertrand,et al. Plasma metabolomics identify hydroxyproline as a potential player in the pathophysiogy of HFpEF , 2022, Archives of Cardiovascular Diseases Supplements.
[5] P. Schlattmann,et al. Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker , 2022, Cells.
[6] Yugang Dong,et al. Signaling cascades in the failing heart and emerging therapeutic strategies , 2022, Signal Transduction and Targeted Therapy.
[7] M. Domingo,et al. Biomarkers in Heart Failure with Preserved Ejection Fraction , 2022, Cardiac failure review.
[8] Tsunehisa Yamamoto,et al. Deranged Myocardial Fatty Acid Metabolism in Heart Failure , 2022, International journal of molecular sciences.
[9] A. Mebazaa,et al. Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC) , 2021, European journal of heart failure.
[10] M. Zahid,et al. Prognosticators of All-Cause Mortality in Patients With Heart Failure With Preserved Ejection Fraction. , 2021, The American journal of cardiology.
[11] A. Mebazaa,et al. Activity of the adrenomedullin system to personalise post-discharge diuretic treatment in acute heart failure , 2021, Clinical Research in Cardiology.
[12] S. Solomon,et al. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. , 2021, JACC. Heart failure.
[13] Christopher J. Rush,et al. Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. , 2021, JAMA cardiology.
[14] A. Palazzuoli,et al. Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes , 2021, Frontiers in Cardiovascular Medicine.
[15] Lyanne M. Kieneker,et al. Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population , 2021, Journal of the American Heart Association.
[16] M. Mcphail,et al. Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute‐on‐Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid–Dependent Monocyte Activation , 2021, Hepatology.
[17] M. Senni,et al. Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. , 2021, Progress in cardiovascular diseases.
[18] A. Hoes,et al. Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction , 2021, European journal of heart failure.
[19] S. Rajagopalan,et al. Endothelin-1 and peak oxygen consumption in patients with heart failure with preserved ejection fraction. , 2021, Heart & lung : the journal of critical care.
[20] F. Wei,et al. Association of long-term SBP with clinical outcomes and quality of life in heart failure with preserved ejection fraction: an analysis of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial , 2021, Journal of hypertension.
[21] Mohammed AlQuraishi,et al. The Role of PKM2 in Metabolic Reprogramming: Insights into the Regulatory Roles of Non-Coding RNAs , 2021, International journal of molecular sciences.
[22] V. Nikolaev,et al. Multifaceted remodelling of cAMP microdomains driven by different aetiologies of heart failure , 2021, The FEBS journal.
[23] D. Maeda,et al. Disproportionately low BNP levels in patients of acute heart failure with preserved vs. reduced ejection fraction. , 2020, International journal of cardiology.
[24] S. Heymans,et al. Natriuretic peptides for the detection of diastolic dysfunction and heart failure with preserved ejection fraction—a systematic review and meta-analysis , 2020, BMC Medicine.
[25] J. Rabinowitz,et al. Comprehensive quantification of fuel use by the failing and nonfailing human heart , 2020, Science.
[26] M. Emdin,et al. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. , 2020, Journal of the American College of Cardiology.
[27] Christoph D. Rau,et al. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis , 2020, International journal of molecular sciences.
[28] Liuqin He,et al. Serine Supports IL-1β Production in Macrophages Through mTOR Signaling , 2020, Frontiers in Immunology.
[29] G. Santulli,et al. Arginine and Endothelial Function , 2020, Biomedicines.
[30] B. Bruneau,et al. Cardiac natriuretic peptides , 2020, Nature Reviews Cardiology.
[31] B. V. Van Tassell,et al. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease , 2020, Circulation research.
[32] Zhuyin Li,et al. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. , 2020, JACC. Heart failure.
[33] L. Hellman,et al. Potent and Broad but not Unselective Cleavage of Cytokines and Chemokines by Human Neutrophil Elastase and Proteinase 3 , 2020, International journal of molecular sciences.
[34] G. Felker,et al. Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction , 2019, Circulation. Heart failure.
[35] Sanjiv J. Shah,et al. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. , 2019, Journal of the American College of Cardiology.
[36] Sanjiv J. Shah,et al. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. , 2019, Journal of the American College of Cardiology.
[37] P. Ponikowski,et al. Clinical value of pre‐discharge bio‐adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission , 2019, European journal of heart failure.
[38] G. Moukarbel,et al. Endothelin 1 Is Associated with Heart Failure Hospitalization and Long-Term Mortality in Patients with Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension , 2019, Cardiology.
[39] B. Heude,et al. Dietary Inflammatory Index and Non-Communicable Disease Risk: A Narrative Review , 2019, Nutrients.
[40] P. Formisano,et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications , 2019, International journal of molecular sciences.
[41] V. Cameron,et al. Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes. , 2019, Journal of the American College of Cardiology.
[42] N. Samani,et al. Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure , 2019, European journal of heart failure.
[43] P. Libby,et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure , 2019, Circulation.
[44] A. Mebazaa,et al. Adrenomedullin in heart failure: pathophysiology and therapeutic application , 2018, European journal of heart failure.
[45] D. Levy,et al. Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes. , 2018, Journal of the American College of Cardiology.
[46] Akshay S. Desai,et al. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction , 2018, Circulation. Heart failure.
[47] P. Ponikowski,et al. Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. , 2018, Journal of the American College of Cardiology.
[48] Sanjiv J. Shah,et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF , 2018, European heart journal.
[49] M. Redfield,et al. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction , 2018, PloS one.
[50] V. Melenovský,et al. Myocardial Injury and Cardiac Reserve in Patients With Heart Failure and Preserved Ejection Fraction. , 2018, Journal of the American College of Cardiology.
[51] A. Voors,et al. Bio‐adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure , 2018, European journal of heart failure.
[52] A. Gavazzi,et al. Prevalence and prognostic impact of non‐cardiac co‐morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community‐based study , 2018, European journal of heart failure.
[53] J. Daubert,et al. Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. , 2018, The American journal of cardiology.
[54] K. Anstrom,et al. Pro‐Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction , 2018, Journal of the American Heart Association.
[55] D. Jacobs,et al. Predictive Value of Collagen Biomarkers for Heart Failure With and Without Preserved Ejection Fraction: MESA (Multi‐Ethnic Study of Atherosclerosis) , 2018, Journal of the American Heart Association.
[56] Liuqin He,et al. Serine prevented high-fat diet-induced oxidative stress by activating AMPK and epigenetically modulating the expression of glutathione synthesis-related genes. , 2018, Biochimica et biophysica acta. Molecular basis of disease.
[57] Hongxing Luo,et al. Quality of inclusion criteria in the registered clinical trials of heart failure with preserved ejection fraction: Is it time for a change? , 2017, International journal of cardiology.
[58] Hua Wang,et al. Circulating microRNAs as novel biomarkers for heart failure. , 2017, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.
[59] T. Nishikimi,et al. Adrenomedullin as a Biomarker of Heart Failure. , 2018, Heart failure clinics.
[60] E. Schelbert,et al. Biological Phenotypes of Heart Failure With Preserved Ejection Fraction. , 2017, Journal of the American College of Cardiology.
[61] H. D. den Ruijter,et al. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction , 2017, European journal of heart failure.
[62] G. Lopaschuk,et al. Complex Energy Metabolic Changes in Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction. , 2017, The Canadian journal of cardiology.
[63] Sanjiv J. Shah. Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction , 2017, Journal of Cardiovascular Translational Research.
[64] C. Yancy,et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association , 2017, Circulation.
[65] A. Mebazaa,et al. Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. , 2017, JACC. Heart failure.
[66] R. D. de Boer,et al. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction , 2017, Journal of the American Heart Association.
[67] J. Daubert,et al. Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach , 2017, Circulation. Cardiovascular genetics.
[68] J. Port,et al. Myocardial microRNAs associated with reverse remodeling in human heart failure. , 2017, JCI insight.
[69] W. März,et al. Prognostic significance of tPA/PAI-1 complex in patients with heart failure and preserved ejection fraction , 2016, Thrombosis and Haemostasis.
[70] R. McKelvie,et al. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. , 2017, Journal of cardiac failure.
[71] M. J. Ferreira,et al. Circulating Biomarkers of Collagen Metabolism and Prognosis of Heart Failure with Reduced or Mid-Range Ejection Fraction. , 2017, Current pharmaceutical design.
[72] K. Anstrom,et al. Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial. , 2016, JACC. Heart failure.
[73] A. Palazzuoli,et al. Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. , 2016, Clinica chimica acta; international journal of clinical chemistry.
[74] Y. Pinto,et al. MicroRNAs in heart failure: from biomarker to target for therapy , 2016, European journal of heart failure.
[75] R. D. de Boer,et al. Biomarkers in heart failure with preserved ejection fraction , 2016, Netherlands Heart Journal.
[76] A. Low,et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction , 2016, European journal of heart failure.
[77] M. Vaduganathan,et al. Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review , 2016, European journal of heart failure.
[78] R. Colbert,et al. Biomarkers in Heart Failure with Preserved Ejection Fraction , 2016 .
[79] E. Rimm,et al. Associations between metabolic dysregulation and circulating biomarkers of fibrosis: the Cardiovascular Health Study. , 2015, Metabolism: clinical and experimental.
[80] David S. Wishart,et al. Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction , 2015, PloS one.
[81] Jacob P. Kelly,et al. Patient selection in heart failure with preserved ejection fraction clinical trials. , 2015, Journal of the American College of Cardiology.
[82] E. Weerapana,et al. Cysteine-mediated redox signalling in the mitochondria. , 2015, Molecular bioSystems.
[83] R. Wachter,et al. Galectin‐3 in patients with heart failure with preserved ejection fraction: results from the Aldo‐DHF trial , 2015, European journal of heart failure.
[84] Michael A. Burke,et al. Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction , 2015, Circulation.
[85] Akshay S. Desai,et al. Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction: Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2014, Circulation. Heart failure.
[86] Rahul C. Deo,et al. Phenotypic spectrum of heart failure with preserved ejection fraction. , 2014, Heart failure clinics.
[87] W. März,et al. C‐reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction , 2014, European journal of heart failure.
[88] B. Greenberg. Heart failure preserved ejection fraction with coronary artery disease: time for a new classification? , 2014, Journal of the American College of Cardiology.
[89] Sanjiv J. Shah,et al. Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: Baseline Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial , 2014, Circulation. Heart failure.
[90] K. Bibbins-Domingo,et al. Soluble Tumor Necrosis Factor Receptors and Heart Failure Risk in Older Adults: Health, Aging, and Body Composition (Health ABC) Study , 2013, Circulation. Heart failure.
[91] L. Liaudet,et al. The role of oxidative stress during inflammatory processes , 2013, Biological chemistry.
[92] D. Fulton,et al. The Subcellular Compartmentalization of Arginine Metabolizing Enzymes and Their Role in Endothelial Dysfunction , 2013, Front. Immunol..
[93] L. Lai,et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. , 2013, Journal of cardiac failure.
[94] J. McMurray,et al. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? , 2012, Journal of the American College of Cardiology.
[95] Eyal Gottlieb,et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2 , 2012, Nature.
[96] G. Lip,et al. A contemporary view on endothelial function in heart failure , 2012, European journal of heart failure.
[97] D. Babuty,et al. Long-Chain Acylcarnitines Regulate the hERG Channel , 2012, PloS one.
[98] R. McKelvie,et al. Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction , 2011, Circulation.
[99] Eric M. Reyes,et al. Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term Outcomes: Data From Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) Linked to Medicare Claims , 2011, Circulation. Heart failure.
[100] W. Paulus,et al. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. , 2011, European heart journal.
[101] A. Wu,et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure , 2011, Circulation. Heart failure.
[102] Hans L Hillege,et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction , 2010, Annals of medicine.
[103] Christopher M O'Connor,et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. , 2010, Journal of the American College of Cardiology.
[104] P. Ponikowski,et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. , 2010, Journal of the American College of Cardiology.
[105] D. J. Veldhuisen,et al. Galectin‐3: a novel mediator of heart failure development and progression , 2009, European journal of heart failure.
[106] B. Jug,et al. Procoagulant state in heart failure with preserved left ventricular ejection fraction. , 2009, International heart journal.
[107] C. Hoppel,et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. , 2009, The Journal of nutrition.
[108] S. Hazen,et al. Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. , 2008, European heart journal.
[109] P. Ponikowski,et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.
[110] E. Benjamin,et al. Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the community. , 2007, American heart journal.
[111] J. Zweier,et al. The role of oxidants and free radicals in reperfusion injury. , 2006, Cardiovascular research.
[112] Yigal M. Pinto,et al. Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.
[113] J. McMurray,et al. Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.
[114] Richard T. Lee,et al. Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction , 2002, Circulation.
[115] E. Schiffrin. Role of endothelin-1 in hypertension and vascular disease. , 2001, American journal of hypertension.
[116] James T. Willerson,et al. Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.